VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
暂无分享,去创建一个
E. Tartour | J. Taieb | A. Carpentier | N. Benhamouda | E. Marcheteau | S. Pernot | O. Colussi | M. Terme | O. Dubreuil | F. Sandoval | Federico Sandoval
[1] L. Zitvogel,et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. , 2012, Cancer research.
[2] L. Zitvogel,et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer , 2012, Oncoimmunology.
[3] Geraint T. Williams,et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer , 2011, Gut.
[4] D. Hanahan,et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. , 2011, Blood.
[5] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[6] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[7] W. Oyen,et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients , 2011, International journal of cancer.
[8] Lin Zhang,et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.
[9] V. Torri,et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[10] E. Thiel,et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. , 2011, European journal of cancer.
[11] D. Nelson,et al. Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model , 2011, Laboratory Investigation.
[12] B. Rini,et al. Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial , 2011, BJU international.
[13] E. Tartour,et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.
[14] Shuji Ogino,et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.
[15] E. Tartour,et al. A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.
[16] J. Allison,et al. Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals , 2010, Clinical Cancer Research.
[17] T. Morisaki,et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg , 2009, European journal of immunology.
[18] J. Zimmer,et al. Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.
[19] M. Koch,et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. , 2009, The Journal of clinical investigation.
[20] W. Sippl,et al. Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT , 2009, PloS one.
[21] D. Klatzmann,et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. , 2009, The Journal of clinical investigation.
[22] C. Divino,et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.
[23] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[24] Masafumi Nakamura,et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. , 2009, Anticancer research.
[25] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[26] D. Mougiakakos,et al. Oxidative stress and lymphocyte persistence: implications in immunotherapy. , 2009, Advances in cancer research.
[27] Jung‐Sik Kim,et al. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. , 2009, Cellular immunology.
[28] D. Mougiakakos,et al. Oxidative stress and lymphocyte persistence: implications in immunotherapy. , 2009, Advances in cancer research.
[29] N. Chaput,et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue , 2008, Gut.
[30] B. Rini,et al. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.
[31] Y. Belkaid,et al. Review Tuning Microenvironments: Induction of Regulatory T Cells by Dendritic Cells Induction of Foxp3 + Treg Cells by Dcs , 2022 .
[32] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[33] P. Brossart,et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.
[34] L. Zitvogel,et al. Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells , 2008, The Journal of Immunology.
[35] E. Aandahl,et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner , 2008, Cancer Immunology, Immunotherapy.
[36] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] K. Jooss,et al. Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.
[38] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[39] A. Akbar,et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo , 2006 .
[40] L. Zitvogel,et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. , 2006, The Journal of Immunology.
[41] M. Beyer,et al. Regulatory T cells in cancer. , 2006, Blood.
[42] M. Ultsch,et al. Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.
[43] A. Akbar,et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. , 2006, The Journal of clinical investigation.
[44] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[45] Shiang Huang,et al. Increased population of CD4+CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients , 2005, European journal of haematology.
[46] B. Chauffert,et al. Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation , 2005, The Journal of experimental medicine.
[47] D. Schuppan,et al. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2005, Biochemical and biophysical research communications.
[48] Yayun Liang,et al. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. , 2005, Endocrinology.
[49] J. Blay,et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.
[50] J. Prieto,et al. CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination 1 , 2003, The Journal of Immunology.
[51] I. Melero,et al. CD4 /CD25 Regulatory Cells Inhibit Activation of Tumor-Primed CD4 T Cells with IFN- -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination , 2003 .
[52] Ethan M. Shevach,et al. CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.
[53] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.